TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
16/04/2025
Voltar para busca
Dado oficial do USPTO
RECOMBUMIN
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
37
Atualização mais recente
08/05/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5
Data de depósito
26/05/2022
Data de registro
23/04/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
23/04/2024
Última transação
08/05/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
98
Localização do titular
GB
Examinador
PERKINS, ELLEN
Unidade examinadora
M10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Sartorius Albumedix Limited
Albumedix Ltd
Representantes
Karen Lim Fross Zelnick Lehrman & Zissu, P.C.
Classificação técnica
Classes Nice
Classe 1Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicals used in industryscience and for use in the manufacture of pharmaceuticals; chemical reagents other than for medical or veterinary purposes; diagnostic reagents and preparationsother than for medical or veterinary purposes; chemical excipients for use in the manufacture of pharmaceutical preparations; proteins for industrial purposes; recombinant human albumin for use as a stabilizer and excipient for industrial purposes and for use in the manufacture of cell culture mediacell and tissue storage and preservation media and for the manufacture of diagnostic imaging agents; cell culture reagents for scientific and research usechemical preservation reagents for scientific and research use; albumin for use in the manufacture of pharmaceutical productsvaccinescellular therapiesregenerative medicines and gene therapies; protein in raw material form for scientific and medical research
Classe 5
Pharmaceuticals for the treatment or prophylaxis of viralbacterialfungalmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalhematologicalophthalmicrespiratorydigestiveneurologicalneurodegenerativeneuromuscularcentral nervous systemgastrointestinalhormonaldermatologicalpsychiatricimmune systemurinaryangiogenicgeneticmenopausalpain related diseases and disorders; pharmaceutical products and substances for the treatment or prophylaxis of viralbacterialfungalmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalhematologicalophthalmicrespiratorydigestiveneurologicalneurodegenerativeneuromuscularcentral nervous systemgastrointestinalhormonaldermatologicalpsychiatricimmune systemurinaryangiogenicgeneticmenopausalpain related diseases and disorders; albuminchemical preparationssynthetic peptidesprotein supplementsmonoclonalpolyclonalimmunologicalnative and recombinant antibodies for medical and veterinary usecells for medical and veterinary useviruseslive viruseslive- attenuated virusesattenuated virusesvirus-like particles and viral vectors for medical and veterinary usevaccinesgrowth factors for medical and veterinary useimmune modulators for medical and veterinary usemonoclonal antibodiesbiological tissue and tissue culturesrecombinant proteins for medical and veterinary usenucleic acid sequencesblood plasmablood components for medical and veterinary useall being for pharmaceutical use for the treatment or prophylaxis of viralbacterialfungalmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalhematologicalophthalmicrespiratorydigestiveneurologicalneurodegenerativeneuromuscularcentral nervous systemgastrointestinalhormonaldermatologicalpsychiatricimmune systemurinaryangiogenicgeneticmenopausalpain related diseases and disorders; reagents for medical use; diagnostic reagents for medical use; protein supplements for pharmaceutical purposes; albuminous preparations for medical or veterinary purposes; recombinant albumin for biological therapeutic purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
37 publicações encontradas
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
16/04/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
16/04/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
16/04/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
16/04/2025
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
11/04/2025
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
09/11/2024
FICS
FINAL DISPOSITION NOTICE SENT TO IB
23/10/2024
FIMP
FINAL DISPOSITION PROCESSED
23/10/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
24/07/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
23/04/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
23/04/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/02/2024
PUBO
PUBLISHED FOR OPPOSITION
06/02/2024
GPNX
NOTIFICATION PROCESSED BY IB
05/02/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
17/01/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
17/01/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
17/01/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
13/01/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
31/12/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
27/12/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
27/12/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/11/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/11/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/11/2023
RFNT
REFUSAL PROCESSED BY IB
23/05/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/05/2023
RFRR
REFUSAL PROCESSED BY MPU
03/05/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
02/04/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
16/03/2023
CNRT
NON-FINAL ACTION WRITTEN
15/03/2023
DOCK
ASSIGNED TO EXAMINER
07/03/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
29/01/2023
MAFR
APPLICATION FILING RECEIPT MAILED
02/08/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
29/07/2022
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
27/07/2022
SDRC
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
21/07/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace RECOMBUMIN ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.